Treatment of von Willebrand disease.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Seminars in hematology (Print)

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1053/J.SEMINHEMATOL.2004.10.001PMID 15662613
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study.

  2004cited by this paper
• Treatment of von Willebrand's Disease.

  2004cited by this paper
• Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIII/VWF concentrate (Humate‐P®)

  2004cited by this paper
• Von Willebrand's disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment.

  2003cited by this paper
• Successful treatment of urgent bleeding in von Willebrand disease with factor VIII/VWF concentrate (Humate‐P®): use of the ristocetin cofactor assay (VWF:RCo) to measure potency and to guide therapy

  2003cited by this paper
• von Willebrand disease: still an intriguing disorder in the era of molecular medicine

  2002cited by this paper
• Venous Thrombosis Following the Use of Intermediate Purity FVIII Concentrate to Treat Patients with Von Willebrand’s Disease

  2002cited by this paper
• Reduced von Willebrand factor survival in type Vicenza von Willebrand disease.

  2002cited by this paper
• Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study.

  2002cited by this paper
• Efficacy and Safety of the Factor VIII/von Willebrand Factor Concentrate, Haemate-P/Humate-P: Ristocetin Cofactor Unit Dosing in Patients with von Willebrand Disease

  2002cited by this paper
• Venous Thromboembolism in Von Willebrand Disease

  2002cited by this paper
• Structure of von Willebrand factor and its function in platelet adhesion and thrombus formation.

  2001cited by this paper
• Congenital von Willebrand disease type I: definition, phenotypes, clinical and laboratory assessment.

  2001cited by this paper
• The Prevalence of von Willebrand Disease in Women with Abnormal Uterine Bleeding

  2001cited by this paper
• Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease

  2000cited by this paper
• Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP.

  2000cited by this paper
• Pregnancy in Women with Type 1 von Willebrand Disease Caused by Heterozygosity for von Willebrand Factor Mutation C1130F

  2000cited by this paper
• High Plasma Concentration of Factor VIIIc Is a Major Risk Factor for Venous Thromboembolism

  2000cited by this paper
• High plasma levels of factor VIII and the risk of recurrent venous thromboembolism.

  2000cited by this paper
• Women and inherited bleeding disorders: pregnancy and delivery.

  1999cited by this paper
• Hemostatic drugs.

  1998cited by this paper
• Clinical management of patients with von Willebrand’s disease with a VHP vWF concentrate: the French experience

  1998cited by this paper
• Frequency of inherited bleeding disorders in women with menorrhagia.

  1998cited by this paper
• Pharmacokinetics, efficacy and safety of Humate‐P® in von Willebrand disease

  1998cited by this paper
• Females with von Willebrand disease: 72 years as the silent majority

  1998cited by this paper
• Pharmacokinetics, efficacy and safety of Humate-P in von Willebrand disease.

  1998cited by this paper
• von Willebrand disease.

  1997cited by this paper
• Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years.

  1997cited by this paper
• Prospective Multicenter Study on Subcutaneous Concentrated Desmopressin for Home Treatment of Patients with von Willebrand Disease and Mild or Moderate Hemophilia A

  1996cited by this paper
• Desmopressin and type II B von Willebrand disease

  1996cited by this paper
• On the value of menorrhagia as a predictor for coagulation disorders

  1996cited by this paper
• Factor VIII: C increases after desmopressin in a subgroup of patients with autosomal recessive severe von Willebrand disease

  1995cited by this paper
• Antibodies to von Willebrand factor in von Willebrand disease.

  1995cited by this paper
• Inhibitors to Coagulation Factors

  1995cited by this paper
• Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis.

  1995cited by this paper
• Posttransfusion anaphylactic reactions in a patient with severe von Willebrand disease: role of complement and alloantibodies to von Willebrand factor.

  1995cited by this paper
• The Reproductive Health of Women with von Willebrand Disease Unresponsive to DDAVP: Results of an International Survey

  1995cited by this paper
• Current Management of von Willebrand’s Disease

  1995cited by this paper
• Biological effect of desmopressin in eight patients with type 2n (‘Normandy’) von Willebrand disease

  1994cited by this paper
• Haemate P in children with von Willebrand's disease.

  1994cited by this paper
• The use of intermediate and high purity factor VIII products in the treatment of von Willebrand disease.

  1994cited by this paper
• Proteolysis of von Willebrand factor in therapeutic plasma concentrates.

  1994cited by this paper
• Desmopressin‐induced thrombocytopenia in type i platelet discordant von willebrand disease

  1993cited by this paper
• Biological effects of a S/D-treated, very high purity, von Willebrand factor concentrate in five patients with severe von Willebrand disease.

  1993cited by this paper
• Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: a cross-over randomized trial.

  1992cited by this paper
• Chromatographic Preparation of a Therapeutic Highly Purified von Willebrand Factor Concentrate from Human Cryoprecipitate

  1992cited by this paper
• Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP)

  1992cited by this paper
• Replacement Therapy with Virus—Inactivated Plasma Concentrates in von Willebrand Disease

  1992cited by this paper
• Alloantibodies in congenital von Willebrand’s disease

  1991cited by this paper
• Nasal spray desmopressin (DDAVP) for mild hemophilia A and von Willebrand disease.

  1991cited by this paper
• Clinical indications for desmopressin (DDAVP) in congenital and acquired von Willebrand disease.

  1991cited by this paper
• Hemostatic effect of normal platelet transfusion in severe von Willebrand disease patients.

  1991cited by this paper
• Assessment of menstrual blood loss using a pictorial chart

  1990cited by this paper
• Consistency of responses to repeated DDAVP infusions in patients with von Willebrand's disease and hemophilia A.

  1989cited by this paper
• DDAVP shortens the prolonged bleeding times of patients with severe von Willebrand disease treated with cryoprecipitate. Evidence for a mechanism of action independent of released von Willebrand factor

  1989cited by this paper
• Hyponatremia and seizures in young children given ddavp

  1989cited by this paper
• Use of a High‐Purity Factor VIII Concentrate (Hemate P) in von Willebrand's Disease 1

  1989cited by this paper
• DDAVP shortens the prolonged bleeding times of patients with severe von Willebrand disease treated with cryoprecipitate. Evidence for a mechanism of action independent of released von Willebrand factor.

  1989cited by this paper
• Hyper‐responsiveness to DDAVP for patients with type I von Willebrand's disease and normal intra‐platelet von Willebrand factor

  1988cited by this paper
• Myocardial infarction in a patient with hemophilia treated with DDAVP.

  1988cited by this paper
• Thrombosis following desmopressin for uremic bleeding

  1988cited by this paper
• Cholecystokinin and glucagonoma.

  1988cited by this paper
• Myocardial infarction in a patient with hemophilia treated with DDAVP.

  1988cited by this paper
• Life‐threatening reaction to factor VIII concentrate in a patient with severe von Willebrand disease and alloantibodies to von Willebrand factor

  1987cited by this paper
• Epidemiological investigation of the prevalence of von Willebrand's disease.

  1987cited by this paper
• DDAVP in type IIa von Willebrand's disease.

  1986cited by this paper
• Pregnancy in women with different types of von Willebrand disease.

  1986cited by this paper
• Heterogeneity of type I von Willebrand disease: evidence for a subgroup with an abnormal von Willebrand factor.

  1985cited by this paper
• Platelet aggregation induced by 1-desamino-8-D-arginine vasopressin (DDAVP) in Type IIB von Willebrand's disease.

  1983cited by this paper
• Multimeric composition of factor VIII/von Willebrand factor following administration of DDAVP: implications for pathophysiology and therapy of von Willebrand's disease subtypes.

  1982cited by this paper
• Multimeric composition of factor VIII/von Willebrand factor following administration of DDAVP: implications for pathophysiology and therapy of von Willebrand's disease subtypes

  1982cited by this paper
• Precipitating antibodies to factor VIII/von Willebrand factor in von Willebrand's disease: effects on replacement therapy.

  1981cited by this paper
• Dysfunctional uterine bleeding in the adolescent.

  1981cited by this paper
• 1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands' diseases.

  1977cited by this paper
• Antihemophilic factor concentrate therapy in von Willebrand disease. Dissociation of bleeding-time factor and ristocetin-cofactor activities.

  1976cited by this paper
• Failure of AHF concentration to control bleeding in von Willebrand's disease.

  1976cited by this paper
• Failure of AHF concentrate to control bleeding in von Willebrand's disease

  1976cited by this paper
• Mechanism of Plasminogen Activator and Factor VIII Increase after Vasoactive Drugs

  1975cited by this paper
• Proceedings: The release of plasminogen activator and factor VIII to lysine vasopressin, arginine vasopressin, I-desamino-8-d-arginine vasopressin, angiotensin and oxytocin in man.

  1974cited by this paper
• Proceedings: The release of plasminogen activator and factor VIII to lysine vasopressin, arginine vasopressin, I-desamino-8-d-arginine vasopressin, angiotensin and oxytocin in man.

  1974cited by this paper
• Letter: Diabetic ketoacidosis.

  1974cited by this paper
• Congenital bleeding disorders with long bleeding time and normal platelet count. II. Von Willebrand's disease (report of thirty-seven patients).

  1968cited by this paper
• Menstrual Blood Loss–A Population Study

  1966cited by this paper
• DETERMINATION OF MENSTRUAL BLOOD LOSS.

  1964cited by this paper
• Transfusion Studies in von Willebrand's Disease: Effect on Bleeding Time and Factor VIII

  1963cited by this paper
• The Treatment of Haemorrhage in von Willebrand's Disease and the Blood Level of Factor VIII (AHG)

  1963cited by this paper

• Navigating the Myriad of von Willebrand Factor Assays

  2020cites this paper
• Type 2M and Type 2A von Willebrand Disease: Similar but Different

  2016cites this paper
• Current therapy in children and adolescents with von Willebrand disease

  2014cites this paper
• Von Willebrand disease

  2014cites this paper
• [Epidural labor analgesia and parturient with type 2B von Willebrand disease].

  2013cites this paper
• Efficacy and safety of Wilate in paediatric VWD patients under 6 years of age – results of a prospective multicentre clinical study including recovery information

  2013cites this paper
• European Study MCMDM-1VWD phenotype in type 1 von Willebrand disease (VWD): results from the Response to desmopressin is influenced by the genotype and

  2013cites this paper
• Generation and optimization of the self‐administered bleeding assessment tool and its validation as a screening test for von Willebrand disease

  2013cites this paper
• Pharmacotherapy of von Willebrand disease

  2013cites this paper
• Chemistry of Hemostasis

  2012cites this paper
• Intravascular recovery of VWF and FVIII following intraperitoneal injection and differences from intravenous and subcutaneous injection in mice

  2012cites this paper
• Hématologie et hémostase

  2011cites this paper
• Hematologic Disease in Pregnancy

  2010cites this paper
• BLEEDING AND HEMOSTASIS DURING NORMO- AND HYPOTHERMIA

  2010cites this paper
• Bleeding and hemostasis during normo- and hypothermia : Studies on porcine and rat models

  2010cites this paper
• Hemostatic and hemorrhagic problems in neurosurgical patients

  2009cites this paper
• How I treat von Willebrand disease.

  2009cites this paper
• eMedicine Specialties > Emergency Medicine > Hematology & Oncology

  2009cites this paper
• The safety of plasma-derived von Willebrand/factor VIII concentrates in the management of inherited von Willebrand disease

  2009cites this paper
• Optimizing treatment of von Willebrand disease by using phenotypic and molecular data.

  2009cites this paper
• Control of bleeding in cancer.

  2009cites this paper
• How I treat How I treat von Willebrand disease

  2009cites this paper
• Von Willebrand disease: 80 year-old without wrinklesl

  2009cites this paper
• Antithrombotic prophylaxis in patients with von Willebrand disease undergoing major surgery: when is it necessary?

  2009cites this paper
• Hematology and Hemostasis

  2008cites this paper
• コンファクトF®を用いた病型不明のvon Willebrand病に合併した卵巣出血の止血管理

  2008cites this paper
• 血液型と出血量との関係—当院における15,857症例の解析—

  2008cites this paper
• Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD.

  2008cites this paper
• Health-Related Hardiness in Individuals With Chronic Illnesses

  2008cites this paper
• Surgical prophylaxis in von Willebrand's disease: a difficult balance to manage.

  2008cites this paper
• The use of desmopressin as a hemostatic agent: A concise review

  2007cites this paper
• Management of inherited von Willebrand disease in 2007

  2007cites this paper
• Recent acquisitions in acquired and congenital von Willebrand disorders.

  2007cites this paper
• The Role Of von Willebrand Factor In Hemorrhagic And Thrombotic Disorders

  2007cites this paper
• Neuraxial anesthesia for cesarean delivery in a parturient with type 1 von Willebrand disease and scoliosis.

  2007cites this paper
• von Willebrand disease: treatment with or without factor VIII?

  2007cites this paper
• Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder

  2007cites this paper
• Evaluation of the clinical safety of desmopressin during pregnancy in women with a low plasmatic von Willebrand factor level and bleeding history.

  2007cites this paper
• Diagnostiek en behandeling van de ziekte van Von Willebrand

  2007cites this paper
• Chapter 6. Von Willebrand Disease

  2007cites this paper
• A multi-center survey of hospital charges for hemophilia and the related diseases in Japan

  2006cites this paper
• Altered Functionality of von Willebrand Factor in Sepsis and Thrombocytopenia — Potential Role of the vWF Cleaving Protease ADAMTS-13

  2006cites this paper
• Phenotypic correction of von Willebrand disease type 3 blood-derived endothelial cells with lentiviral vectors expressing von Willebrand factor.

  2006cites this paper
• Advances in the diagnosis and management of von Willebrand disease

  2006cites this paper
• Von Willebrand's disease: clinical management

  2006cites this paper
• von Willebrand factor: a prima ballerina on two different stages.

  2005cites this paper
• Characterization, Classification, and Treatment of von Willebrand Diseases: A Critical Appraisal of the Literature and Personal Experiences

  2005cites this paper
• Are thrombotic complications in patients with von Willebrand's disease expression of a multifactorial disease?

  2005cites this paper
• Diagnosis and management of mild bleeding disorders.

  2005cites this paper